Rubicon Research IPO Last Date, Price & Prospectus PDF
| ➡️ Get instant news updates on Whatsapp. Click here to join our Whatsapp Group. |
Rubicon Research has released IPO and all details of IPO such as last date to apply, price, prospectus PDF and all other details are given below.
Rubicon Research IPO Details
| IPO Open Date | October 9, 2025 |
| IPO Close Date | October 13, 2025 |
| Face Value | ₹1 Per Equity Share |
| IPO Price Band | ₹461 to ₹485 Per Share |
| Issue Size | Approx ₹1,377.50 Crores |
| Fresh Issue | Approx ₹500 Crores |
| Offer for Sale | Approx 1,80,92,762 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE, NSE |
| Download Prospectus PDF | Click Here |
Rubicon Research IPO Dates and Schedule
| IPO Open Date | October 9, 2025 |
| IPO Close Date | October 13, 2025 |
| Basis of Allotment | October 14, 2025 |
| Refunds | October 15, 2025 |
| Credit to Demat Account | October 15, 2025 |
| IPO Listing Date | October 16, 2025 |
| IPO Bidding Cut-off Time | October 13, 2025 – 5 PM |
About Rubicon Research IPO
Rubicon Research Limited, incorporated in 1999, is a pharmaceutical company involved in developing, manufacturing, and marketing specialized formulations. As of June 30, 2025, the company had a portfolio of 72 products approved by the US FDA under ANDA and NDA, out of which 66 products were already commercialized. These products operate in a US generic pharmaceutical market worth USD 2,455.7 million, and Rubicon Research contributed USD 195 million to this market in Fiscal 2024.
The company has 17 new products waiting for US FDA approval and 63 more products at different stages of development. As of June 30, 2025, Rubicon marketed over 350 SKUs to 96 customers, including three large wholesalers who account for more than 90% of wholesale drug distribution in the US. Its customer base also includes group purchasing organizations, national and regional pharmacy chains, and managed care organizations.
Outside the US, Rubicon Research has registered or filed 48 product applications across Australia, the UK, Singapore, Saudi Arabia, and the UAE, with plans to begin commercial activities once approvals are granted. The company also offers contract manufacturing services to customers in India, Australia, and New Zealand.
Rubicon operates three manufacturing plants in India and two R&D facilities that are inspected by the US FDA, one in India and one in Canada. Its main strengths include being one of the fastest-growing Indian pharmaceutical companies, using a data-driven approach to product selection, having strong R&D and sales capabilities, maintaining a solid record of compliance with cost-effective manufacturing, and being guided by an experienced and entrepreneurial management team.
